The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Methotrexate Loaded Polyether-Copolyester Dendrimers for the Treatment of Gliomas: Enhanced Efficacy and Intratumoral Transport Capability
Abstract
Therapeutic benefit in glial tumors is often limited due to low permeability of delivery systems across the blood-brain barrier (BBB), drug resistance, and poor penetration into the tumor tissue. In an attempt to overcome these hurdles, polyether-copolyester (PEPE) dendrimers were evaluated as drug carriers for the treatment of gliomas. Dendrimers were conjugated to d-glucosamine as the ligand for enhancing BBB permeability and tumor targeting. The efficacy of methotrexate (MTX)-loaded dendrimers was established against U87 MG and U 343 MGa cells. Permeability of rhodamine-labeled dendrimers and MTX-loaded dendrimers across the in vitro BBB model and their distribution into avascular human glioma tumor spheroids was also studied. Glucosylated dendrimers were found to be endocytosed in significantly higher amounts than nonglucosylated dendrimers by both the cell lines. IC 50 of MTX after loading in dendrimers was lower than that of the free MTX, suggesting that loading MTX in PEPE dendrimers increased its potency. Similar higher activity of MTX-loaded glucosylated and nonglucosylated dendrimers was found in the reduction of tumor spheroid size. These MTX-loaded dendrimers were able to kill even MTX-resistant cells highlighting their ability to overcome MTX resistance. In addition, the amount of MTX-transported across BBB was three to five times more after loading in the dendrimers. Glucosylation further increased the cumulative permeation of dendrimers across BBB and hence increased the amount of MTX available across it. Glucosylated dendrimers distributed through out the avascular tumor spheroids within 6 h, while nonglucosylated dendrimers could do so in 12 h. The results show that glucosamine can be used as an effective ligand not only for targeting glial tumors but also for enhanced permeability across BBB. Thus, glucosylated PEPE dendrimers can serve as potential delivery system for the treatment of gliomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Kojima, C., Kono, K., Maruyama, K., & Takagishi, T. (2000) · Bioconjugate Chemistry · doi:10.1021/bc0000583 · Cited by 663
Pardridge, W. M., Boado, R. J., & Farrell, C. R. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)38267-x · Cited by 606
PATRI, A., KUKOWSKALATALLO, J., & BAKERJR, J. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.014 · Cited by 597
Binding and interstitial penetration of liposomes within avascular tumor spheroids
Kostarelos, K., Emfietzoglou, D., Papakostas, A., Yang, W., Ballangrud, Å., & Sgouros, G. (2004) · International Journal of Cancer · doi:10.1002/ijc.20457 · Cited by 127
Optimising non-viral gene delivery in a tumour spheroid model
Mellor, H. R., Davies, L. A., Caspar, H., Pringle, C. R., Hyde, S. C., Gill, D. R., & Callaghan, R. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.947 · Cited by 49
Cited by
Astruc, D., Boisselier, E., & Ornelas, C. (2010) · Chemical Reviews · doi:10.1021/cr900327d · Cited by 1,844
Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy
Mehta, G., Hsiao, A. Y., Ingram, M., Luker, G. D., & Takayama, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.045 · Cited by 1,172
Dendrimer toxicity: Let's meet the challenge
Jain, K., Kesharwani, P., Gupta, U., & Jain, N. K. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.04.027 · Cited by 710
Biomedical applications of dendrimers: a tutorial
Mintzer, M. A., & Grinstaff, M. W. (2011) · Chem. Soc. Rev. · doi:10.1039/b901839p · Cited by 671
Dendrimers as Carriers for Delivery of Chemotherapeutic Agents
Medina, S. H., & El-Sayed, M. E. H. (2009) · Chemical Reviews · doi:10.1021/cr900174j · Cited by 669
Cheng, Y., Zhao, L., Li, Y., & Xu, T. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00097c · Cited by 515
Nanotechnological advances for the delivery of cns therapeutics.
Wong, H. L., Wu, X. Y., & Bendayan, R. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.10.007 · Cited by 488
Hersh, A. M., Alomari, S., & Tyler, B. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084153 · Cited by 478
Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals
Ying, X., Wen, H., Lu, W.-L., Du, J., Guo, J., Tian, W., Men, Y., Zhang, Y., Li, R.-J., Yang, T.-Y., et al. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.09.020 · Cited by 447
Xin, H., Jiang, X., Gu, J., Sha, X., Chen, L., Law, K., Chen, Y., Wang, X., Jiang, Y., & Fang, X. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.02.044 · Cited by 384
Dendrimers: A versatile nanocarrier for drug delivery and targeting
Sherje, A. P., Jadhav, M., Dravyakar, B. R., & Kadam, D. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.07.030 · Cited by 373
Advancements in nanoparticle-based treatment approaches for skin cancer therapy
Zeng, L., Gowda, B. H. J., Ahmed, M. G., Abourehab, M. A. S., Chen, Z.-S., Zhang, C., Li, J., & Kesharwani, P. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01708-4 · Cited by 365
Agrawal, M., Ajazuddin, Tripathi, D. K., Saraf, S., Saraf, S., Antimisiaris, S. G., Mourtas, S., Hammarlund-Udenaes, M., & Alexander, A. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.05.019 · Cited by 356
Multifunctional nanoparticles for brain tumor imaging and therapy
Cheng, Y., Morshed, R. A., Auffinger, B., Tobias, A. L., & Lesniak, M. S. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.006 · Cited by 349
Xin, H., Sha, X., Jiang, X., Zhang, W., Chen, L., & Fang, X. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.07.046 · Cited by 311
Li, Y., He, H., Jia, X., Lu, W.-L., Lou, J., & Wei, Y. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.02.004 · Cited by 310
PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors
He, H., Li, Y., Jia, X.-R., Du, J., Ying, X., Lu, W.-L., Lou, J.-N., & Wei, Y. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.09.002 · Cited by 303
Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs
Naqvi, S., Panghal, A., & Flora, S. J. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00494 · Cited by 305
Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors
Bhowmik, A., Khan, R., & Ghosh, M. K. (2015) · BioMed Research International · doi:10.1155/2015/320941 · Cited by 291
Nano carriers for drug transport across the blood–brain barrier
Li, X., Tsibouklis, J., Weng, T., Zhang, B., Yin, G., Feng, G., Cui, Y., Savina, I. N., Mikhalovska, L. I., Sandeman, S. R., et al. (2017) · Journal of Drug Targeting · doi:10.1080/1061186x.2016.1184272 · Cited by 282
Nanotechnology—novel therapeutics for CNS disorders
Srikanth, M., & Kessler, J. A. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.76 · Cited by 198
Oliveira, J. M., Salgado, A. J., Sousa, N., Mano, J. F., & Reis, R. L. (2010) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2010.04.006 · Cited by 182
Huang, B.-W., & Gao, J.-Q. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.005 · Cited by 174
Application of nanoparticles on diagnosis and therapy in gliomas.
Hernández-Pedro, N. Y., Rangel-López, E., Magaña-Maldonado, R., de la Cruz, V. P., Santamaría del Angel, A., Pineda, B., & Sotelo, J. (2013) · BioMed Research International · doi:10.1155/2013/351031 · Cited by 84
Zhang, C.-X., Zhao, W.-Y., Liu, L., Ju, R.-J., Mu, L.-M., Zhao, Y., Zeng, F., Xie, H.-J., Yan, Y., & Lu, W.-L. (2015) · Oncotarget · doi:10.18632/oncotarget.5354 · Cited by 38
Metadata
- Authors
- Dhanikula, R. S., Argaw, A., Bouchard, J.-F., & Hildgen, P.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-01-03
- Volume
- 5
- Issue
- 1
- Pages
- 105-116
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W1969388062
- Cited by
- 246
- References
- 6
- FWCI
- 13.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.